

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Origins of Cystic Fibrosis Lung Disease

David A. Stoltz, M.D., Ph.D., David K. Meyerholz, D.V.M., Ph.D.,
and Michael J. Welsh, M.D.

AT THE BASIC LEVEL, WE KNOW THE GENETIC CAUSE OF CYSTIC FIBROSIS: it is an autosomal recessive disease caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR).^{1,2} At the clinical level, we know that chronic bacterial airway infection, prominent neutrophilic inflammation and mucus in airways, and progressive bronchiectasis characterize advanced cystic fibrosis lung disease, which causes most morbidity and death in people with cystic fibrosis.² Between those two extremes, the way in which loss of CFTR-mediated chloride and bicarbonate transport leads to chronic airway infection has remained uncertain.

Over the past two decades, investigators have conducted studies involving people with cystic fibrosis (defined as persons who carry known disease-causing CFTR mutations) at progressively earlier time points. We have learned that bronchiectasis is present in nearly one in three children with cystic fibrosis by 3 years of age,³ although the host-defense defects that trigger infection continue to be debated.⁴⁻¹⁰ Even before the onset of symptoms, pulmonary inflammation and infection are often present, although which condition comes first has been uncertain.^{11,12} Findings on chest computed tomography (CT) are abnormal in most babies with cystic fibrosis as early as 3 months of age,¹³ although the relative contribution of inflammation, airway remodeling, and other factors remains undefined. Studies involving children at even earlier ages might reveal the origins of cystic fibrosis lung disease and thereby change clinical practice.

Indeed, simply knowing that disease begins before symptoms develop has been a factor driving cystic fibrosis centers to intervene early, and the outcomes have been encouraging.¹⁴ Understanding the initial host-defense defects in the airways of people with cystic fibrosis could suggest new preventions and treatments, as well as the means to assess disease status and the efficacy of therapeutic agents. Additional reasons to elucidate the origins of this disease are the implementation of universal screening to detect cystic fibrosis in newborns and potential new therapeutic agents that target CFTR.¹⁵⁻¹⁷ However, access to organs and tissue in newborns is extremely limited, and the invasive *in vivo* and *ex vivo* experimental interventions required to elucidate the pathogenesis most often cannot be performed in humans.

The lack of an animal model that mirrors cystic fibrosis in humans has hindered progress in discovering the origins of the lung disease.¹⁸ Respiratory disease such as that in humans does not develop in mice with *cftr* mutations. However, lung disease that mimics that in humans with cystic fibrosis occurs in other recently generated animal models. In this review, we focus primarily on the newborn period, because this time window is key to discovering the origins of cystic fibrosis airway disease.

NEW ANIMAL MODELS THAT MIRROR CYSTIC FIBROSIS IN HUMANS

To circumvent the limitations of studying cystic fibrosis in mice and humans, investigators have developed new animal models of cystic fibrosis in pigs, ferrets,

From the Departments of Internal Medicine (D.A.S., M.J.W.), Molecular Physiology and Biophysics (D.A.S., M.J.W.), and Pathology (D.K.M.) and the Howard Hughes Medical Institute (M.J.W.), Roy J. and Lucille A. Carver College of Medicine, and the Department of Biomedical Engineering (D.A.S.), University of Iowa, Iowa City. Address reprint requests to Dr. Stoltz at the University of Iowa Carver College of Medicine, 6322 PBDB, 169 Newton Rd., Iowa City, IA 52242, or at david-stoltz@uiowa.edu; or to Dr. Meyerholz at the University of Iowa Carver College of Medicine, 1165 ML, 169 Newton Rd., Iowa City, IA 52242, or at david-meyerholz@uiowa.edu; or to Dr. Welsh at the Howard Hughes Medical Institute, University of Iowa Carver College of Medicine, 6332 PBDB, 169 Newton Rd., Iowa City, IA 52242, or at michael-welsh@uiowa.edu.

N Engl J Med 2015;372:351-62.

DOI: 10.1056/NEJMra1300109

Copyright © 2015 Massachusetts Medical Society.

and rats.¹⁹⁻²¹ We focused on pigs because, as compared with mice, their anatomical, physiological, biochemical, and genetic characteristics, as well as their size and life span, are more similar to those in humans.²² Because embryonic stem cells that can contribute to the germ line had been developed only for mice, a different approach was required. We and our colleagues modified the *cftr* gene in porcine fetal fibroblasts and then used them for somatic-cell nuclear transfer (the procedure that was used in cloning Dolly the sheep) to produce pigs with cystic fibrosis.¹⁹ With the exception of mice, these pigs were the first mammalian disease models generated by targeted gene modification.

Pigs that lack CFTR have a phenotype like that which is typically observed in people with cystic fibrosis, including meconium ileus, exocrine

pancreatic destruction, focal biliary cirrhosis, atresia of the vas deferens, an abnormally small gallbladder, and abnormal glucose homeostasis (early cystic fibrosis–related diabetes mellitus).^{19,23-25} Within weeks to months after birth, airway and nasal sinus disease with hallmark features of cystic fibrosis (infection, inflammation, tissue remodeling, mucus accumulation, and obstruction) develops spontaneously in pigs with cystic fibrosis (Fig. 1).²⁶⁻²⁸ As is the case in humans, the appearance of airway disease is heterogeneous, both within and among pigs.²⁶⁻²⁹ Pigs bearing the common cystic fibrosis–associated mutation, $\Delta F508$ -*cftr*, also have characteristic features that mirror those of cystic fibrosis in humans; these include intestinal, pancreatic, and airway disease.²⁷

A similar gene-targeting strategy was used to produce ferrets lacking CFTR.²⁰ Intestinal, airway, and reproductive features consistent with human disease develop in ferrets with cystic fibrosis; these animals may be particularly valuable for studying cystic fibrosis–related diabetes mellitus.^{20,30-33} Rats with a disrupted *cftr* gene were recently produced with the use of zinc-finger endonuclease techniques.²¹ Intestinal, airway, and reproductive features consistent with human disease also develop in them.

LOSS OF CFTR FUNCTION AND CONGENITAL AIRWAY ABNORMALITIES




Figure 1. Pathologic Features of Airway Disease in Humans and Pigs with Cystic Fibrosis.

Histologic images (hematoxylin and eosin) of the lungs of a 3-month-old infant with cystic fibrosis (Panel A) and a 2-month-old pig with cystic fibrosis (Panel B) are shown. Neutrophilic inflammation (arrows) obstructs the airway lumens.

Since airway obstruction occurs early in the lives of babies with cystic fibrosis,^{13,34,35} the question has been raised regarding whether obstruction might, in part, be congenital. A similar question has been asked regarding hypoplasia of the nasal sinuses, which has been well described in people with cystic fibrosis.³⁶ CFTR is expressed early during development,³⁷ so in utero alterations are plausible. Indeed, studies in mice, pigs, and rats with cystic fibrosis shortly after birth reveal structural tracheal abnormalities, including narrowed proximal airways with assorted alterations in airway cartilage, hypoplastic submucosal glands, and prominent airway smooth-muscle bundles^{21,27,38,39} (Fig. 2). The presence of this congenital defect in mice with cystic fibrosis, which lack other respiratory abnormalities associated with this disease, suggests a distinct mechanism for this defect. Hypoplastic nasal sinuses are also present at birth in piglets with cystic fibro-

sis (Fig. 2)²⁸; this suggests that a primary cystic fibrosis defect contributes to these congenital changes. These abnormalities may have physiological significance, because newborn piglets with cystic fibrosis have airflow obstruction and air trapping in the absence of inflammation or mucus obstruction (Fig. 2).⁴⁰

Congenital abnormalities in three species suggest that humans might also have altered airway development. A reappraisal of reported autopsy findings⁴¹ from the tracheas of infants who were younger than 2 weeks of age showed that babies with cystic fibrosis had narrowed tracheas, a finding that was similar to that seen in newborn animal models.³⁸ Furthermore, a recent study showed that 15% of young children with cystic fibrosis (median age, 16 months) had bronchoscopic evidence of tracheomalacia, which was associated with more severe airway disease.⁴² Thus, the airway obstruction and air trapping observed in infants with cystic fibrosis as early as 2 to 3 months of age^{34,35} might, at least in part, be congenital in nature.

REDUCED CHLORIDE SECRETION, NOT SODIUM HYPERABSORPTION

Cystic fibrosis alters the electrophysiological properties across airway epithelia, and measures of nasal voltage have been used to aid in the diagnosis and assessment of the effectiveness of interventions.^{2,15} Two processes determine the bulk of the electrophysiological characteristics — CFTR-mediated anion (chloride and bicarbonate) secretion and epithelial sodium channel-mediated sodium absorption.² Alterations in either process might change electrophysiological properties.

The airway epithelia in newborn pigs with cystic fibrosis, which extend from the nose to the bronchi, lack cyclic AMP-stimulated chloride secretion.⁴³ This is expected because CFTR is an apical membrane anion channel that is regulated by phosphorylation with cyclic AMP-dependent protein kinase. These findings are consistent with those in studies of the airway epithelia of ferrets,^{20,31} rats,²¹ and humans with cystic fibrosis²; these epithelia consistently have a loss of anion permeability. In addition, the salt concentration in airway-surface liquid is similar in wild-type newborn pigs and in those with cystic fibrosis.⁴⁴

A widely held hypothesis is that CFTR inhibits the epithelial sodium channel and that loss of

that effect causes amiloride-inhibitable sodium hyperabsorption, which dehydrates airways, reduces the height of the periciliary liquid layer, and disrupts mucociliary clearance.^{9,45-47} Studies of cultured human airway epithelia, as well as of mouse fibroblasts and dog kidney-cell lines (both of which were expressing recombinant CFTR and epithelial sodium channels), suggest that without CFTR, epithelial sodium channel-mediated sodium absorption increases.^{9,45-47} In addition, mice with overexpression of the epithelial sodium channel have decreased height of the periciliary liquid layer and reduced mucociliary clearance,^{9,45-47} suggesting that increased activity of epithelial sodium channels can alter airway-surface liquid.

Airway epithelia in newborn pigs with cystic fibrosis do not hyperabsorb sodium, a finding that contrasts with the hypothesis that sodium hyperabsorption initiates disease.⁴³ Studies involving neonatal ferrets with cystic fibrosis^{31,32} and 3-to-6-week-old rats with cystic fibrosis,²¹ as well as some studies of airway epithelia in humans with cystic fibrosis,⁴⁸ also showed no evidence of increased sodium absorption. In addition, two other human tissues that express both CFTR and the epithelial sodium channel — sweat-gland ducts and submucosal glands — do not hyperabsorb sodium in cystic fibrosis.^{4,49,50} Secondary changes in airways might increase sodium absorption as the disease progresses, but data suggest that loss of CFTR does not directly increase activity of the epithelial sodium channel at the genesis of disease. Nevertheless, in the nasal epithelia of both humans and pigs with cystic fibrosis, as compared with controls, amiloride inhibits a greater fraction of the transepithelial voltage and short-circuit current, which is sometimes taken to indicate increased sodium absorption. Sweat-gland ducts show similar changes without hyperabsorbing sodium. How is this apparent paradox explained? The CFTR chloride conductance and the epithelial sodium channel conductance sit in parallel in the apical membrane, and elimination of the chloride conductance (a shunt pathway, in part) magnifies sodium-dependent electrophysiological properties without increasing sodium absorption.⁴³

LOSS OF CFTR AND REDUCED PH OF AIRWAY-SURFACE LIQUID

CFTR conducts bicarbonate,⁵¹ and loss of CFTR eliminates bicarbonate secretion by airway epi-




Figure 2 (facing page). Structural Airway Abnormalities in Cystic Fibrosis.

Panel A shows three-dimensional reconstructions from microcomputed tomographic images of the laryngeal and upper tracheal region of mice with cystic fibrosis and wild-type controls at 6 to 8 weeks of age. The structure of the cartilage rings (yellow) is disrupted, and the tracheal lumen (purple) is narrowed in mice with cystic fibrosis. Panel B shows three-dimensional reconstructions based on optical coherence tomographic images of tracheal cartilage rings in newborn pigs. Different colors indicate the individual cartilage rings. Images courtesy of Drs. Melissa Suter (Massachusetts General Hospital) and Eman Namati (University of Iowa). Panel C shows three-dimensional reconstructions based on computed tomographic (CT) images of ethmoid (red) and maxillary (green) sinuses in newborn pigs. Hypoplastic ethmoid sinuses are shown in pigs with cystic fibrosis. Panel D shows a chest CT image of a piglet with cystic fibrosis on the day of birth and before the development of airway infection, inflammation, and mucus obstruction. Air trapping (arrows), a sign of airway obstruction, is already present. Panel E shows air trapping (arrows) on a CT image of the chest of a 14-month-old baby with cystic fibrosis. Murine tracheas were provided by Drs. Craig Hodges and Mitchell Drumm (Case Western Reserve University) and analyzed by Ryan Adam (University of Iowa). Sinus image analysis was performed by Dr. Eugene Chang and Tanner Wallen (University of Iowa).

thelia in pigs.⁴³ As a result, the airway-surface liquid of newborn piglets with cystic fibrosis has a reduced pH when measured *in vivo*, *ex vivo*, and in cultured epithelia (Fig. 3A).⁴⁴ These findings are in accord with earlier reports that cultured human airway epithelia from patients with cystic fibrosis lack bicarbonate secretion,⁵³ that the pH of the airway-surface liquid of these epithelia is acidic,⁵⁴ and that secretions from their submucosal glands are abnormally acidic.⁵⁵ A small study involving infants with cystic fibrosis also showed that the pH in the nasal airway-surface liquid was lower in those infants than it was in infants without cystic fibrosis.⁵⁶ However, in older children and adults, genotype-dependent differences in the pH of nasal airway-surface liquid may be more variable.⁵⁶⁻⁵⁸ The reasons for this variability remain to be determined.

AIRWAY INFECTION PRECEDING LUNG INFLAMMATION

The chicken-and-egg conundrum about infection and inflammation has long vexed researchers and


clinicians in the field.^{6,10-12,59} During the first hours after birth, piglets with cystic fibrosis show no evidence of inflammation in their airways on histopathological analysis, measurement of cell counts and cytokines, or transcript analysis.^{19,26,27,38} Yet, after a pulmonary challenge with *Staphylococcus aureus*, they fail to eradicate bacteria as well as do the airways of controls.²⁶ Moreover, newborn piglets and neonatal ferrets with cystic fibrosis harbor more bacteria than do littermates without this disease.^{26,32}

The species that are isolated include a wide variety of gram-positive and gram-negative organisms, including *S. aureus*. Although *Pseudomonas aeruginosa* is rare in young pigs with cystic fibrosis, it infects older pigs that have clinical disease.^{28,29} A similar pattern occurs in cystic fibrosis in humans; during the initial months to years of life, a wide variety of bacteria are recovered from the lungs.^{14,60} With time, the lungs become chronically colonized with a more restricted number of species, most notably *P. aeruginosa*.¹⁴

These findings indicate that within hours after birth, infants with cystic fibrosis have an “equal opportunity” host-defense defect in their lungs that impairs eradication of many different types of bacteria. That abnormality can initiate a cascade of airway inflammation and airway remodeling. Later in life, the types of infection narrow to a few predominant species, probably because of an interplay between a changing host and bacterial genetic adaptations. In addition, although infection precedes inflammation, subsequent inflammatory responses, resolution of inflammation, adaptive immune responses, or all of these might be abnormal.¹⁰

ACIDIC AIRWAY-SURFACE LIQUID THAT IMPAIRS BACTERIAL KILLING

Airways use multiple mechanisms to protect lungs against infection. One important defense is the complex soup of antimicrobial peptides, proteins, and lipids in airway-surface liquid. Alexander Fleming was the first to identify one of these — lysozyme — after he noticed that sneeze droplets killed bacteria on his culture dish.⁶¹ Since then, more factors have been identified, including lactoferrin, defensins, cathelicidins, and secretory leukocyte peptidase inhibitor.⁶² Many of these factors have individual as well as synergistic effects that rapidly kill bacteria.⁶³



In wild-type piglets, airway-surface liquid very quickly kills most *S. aureus* (Fig. 3B).⁴⁴ In contrast, loss of CFTR reduces rapid bacterial killing by about half. This is not due to a decreased abundance of antimicrobials in airway-surface liquid. Rather, the reduced pH of airway-surface liquid in piglets with cystic fibrosis inhibits its antimicrobial activity. Increasing the pH of air-




Figure 4. Accumulation of Mucus in Humans and Animals with Cystic Fibrosis.

Panels A through E show the “stringy” appearance of mucus arising from glands. Mucus secreted from submucosal glands in pulmonary airways remained in the gland duct in a 7-month-old baby with cystic fibrosis (Panel A), a 2-month-old pig with cystic fibrosis (Panel B), and an 8-month-old ferret with cystic fibrosis (Panel C, reproduced from Sun et al.³² with permission from the publisher). Mucus also emerged from submucosal glands in ethmoid sinus olfactory epithelium that did not contain goblet cells in a 1-month-old pig with cystic fibrosis (Panel D). Similar to mucus from submucosal glands, mucus arising from colonic crypts of newborn pigs with cystic fibrosis can have a stringy appearance and adherence to the site of origin (Panel E). Panels F through I show the lamellar appearance of mucus along epithelia. In affected intrapulmonary airways in a 2-month-old pig with cystic fibrosis, mucus has a lamellar appearance lying along airway walls (Panel F). A similar pattern of mucus arising from goblet cells is shown in the ethmoid sinuses of a 1-month-old pig with cystic fibrosis. The respiratory epithelium of the ethmoid sinuses lacks submucosal glands, and mucus can sometimes be traced back to the cells of origin (Panel G). Likewise, mucus can have a lamellar appearance and be traced back to the cell of origin in the gallbladder of a newborn pig with cystic fibrosis (Panel H). Pancreatic ducts are obstructed by mucus in a 6-month-old pig with cystic fibrosis (Panel I).


way-surface liquid by aerosolizing sodium bicarbonate onto the airways of piglets with cystic fibrosis corrects the bacterial-killing defect (Fig. 3C). Conversely, increasing the acidity of airway-surface liquid diminishes bacterial killing in wild-type piglets.

These findings directly link loss of CFTR function to a host-defense defect; without CFTR-dependent bicarbonate secretion, the pH of airway-surface liquid decreases and antibacterial activity is impaired. The reduced degree of bacterial killing may be one of the critical first steps in a downward

spiral from a sterile newborn lung to one that is chronically colonized.

FAILURE OF MUCUS TO DETACH FROM SUBMUCOSAL GLAND DUCTS

Another important airway defense is mucociliary transport, which guards the lung by trapping invading pathogens and particulates in mucus that is then propelled up the airways by cilia.^{64,65} Although people with advanced cystic fibrosis can have slowed mucociliary transport,⁶⁵ wheth-



er mucociliary transport is impaired at the origin of the disease has been unknown.^{65,66}

Mucociliary transport, assayed with the use of a CT-based approach to track discrete airway particles, appears to be similar in wild-type newborn piglets and in newborn piglets with cystic fibrosis under basal conditions.^{52,67} However, after cholinergic stimulation, which elicits copious mu-

cus secretion from submucosal glands, many particles move normally in piglets with cystic fibrosis, but some become stuck and fail to move up the airways (Fig. 3D). Mechanistic investigations of excised airways reveal that submucosal glands in piglets with cystic fibrosis secrete strands and blobs of mucus that sometimes do not break free after emerging and remain anchored to the

Figure 5 (facing page). Model of Host-Defense Defects in the Airway of a Person with Cystic Fibrosis.

As shown in Panel A, healthy airways are protected from inhaled and aspirated bacteria that enter the lung. The airway-surface liquid (left) contains endogenous antimicrobial agents that kill bacteria. Mucociliary transport (right), consisting of motile cilia and mucus produced by submucosal glands and goblet cells, sweeps bacteria out of the lung. CFTR and possibly CFTR-associated transporters provide a pathway for the exit of chloride and bicarbonate across the apical membrane of cells in the surface epithelium and in the submucosal glands. As shown in Panel B, the airway of a person with cystic fibrosis has at least two host-defense defects at the genesis of the disease. Loss of CFTR channels that conduct chloride (Cl^-) and bicarbonate (HCO_3^-) onto the airway surface causes the pH of the airway-surface liquid to decrease, and the acidic airway-surface liquid inhibits antimicrobial activity. Loss of CFTR channels in submucosal glands causes mucus to develop abnormal properties so that it does not break free after emerging and remains anchored to the gland ducts. As shown in Panel C, when bacteria enter healthy airways (top), they are killed by the antimicrobial activity of airway-surface liquid, mucociliary transport sweeps them out of the lung, and other defenses, including phagocytic cells, eradicate them to maintain sterile lungs. In persons with cystic fibrosis (bottom), antimicrobial activity and mucociliary transport are less effective than in healthy persons, and other defenses may also be impaired. Eventually, the host defenses are overwhelmed, and bacteria proliferate, with inflammation, remodeling, immunity, and genetic adaptation in the bacteria influencing the species that will dominate. In addition, the resulting inflammation and airway remodeling may further enhance or impair host-defense mechanisms.

gland ducts, hindering mucociliary transport (Fig. 3E). The defect in mucociliary transport is not attributable to depletion of periciliary liquid, because the defect persists when the airway surface is submerged in saline. Inhibition of anion secretion in the airways of wild-type pigs replicates the abnormalities associated with cystic fibrosis. These results were predicted by earlier analyses⁵ from the laboratory of Wine, as well as by studies,⁶⁸ performed in the laboratory of Ballard, of the airways of wild-type pigs treated with agents that inhibit anion secretion. These data are consistent with findings of slowed mucociliary clearance in the excised trachea of 3-to-8-month-old ferrets.³² They are also in concert with the findings of a study that showed that slowed tracheal mucociliary transport in the excised trachea of piglets with cystic fibrosis was not related to reduced depth of the periciliary liquid.⁶⁹

These findings directly link impaired mucociliary transport to loss of CFTR anion transport, indicating that defective mucociliary transport is a primary abnormality that is not dependent on infection, inflammation, or remodeling. Nevertheless, advancing infection and bronchiectasis might further disrupt mucociliary transport and fuel disease progression. Data also suggest that the environment of the submucosal gland lumen into which mucus is initially secreted probably alters its properties, causing abnormal detachment. It remains uncertain whether defective bicarbonate secretion, liquid secretion, or a combination of these factors is the key requirement for abnormal mucociliary transport.^{52,68,70-72} Abnormal airway-surface liquid might also alter the properties of mucus secreted from goblet cells.

The finding that mucus abnormalities are a problem in the lungs of persons with cystic fibrosis has parallels with findings in other organs.^{71,72} In emphasizing the contributions of defective bicarbonate secretion and abnormal mucus, Quinton referred back to one of the early names for the disease — mucoviscidosis.⁷¹ Indeed, there is a rogues' gallery of mucus abnormalities in multiple organs, including the lungs, intestine, pancreas, and gallbladder of pigs, ferrets, and humans with cystic fibrosis (Fig. 4).

ADDITIONAL IMPLICATIONS AND SPECULATIONS

Discoveries from new animal models raise additional questions for future research and have implications for the care of people with cystic fibrosis, although any therapeutic implications will require assessment in humans. In addition, whether defects that are key at the origins of cystic fibrosis retain pathophysiological importance later in the disease course remains uncertain. The following paragraphs review some of the take-home points of this article.

First, the consensus based on the data reviewed here and clinical experience is that people with cystic fibrosis should be treated early. We suspect that host-defense defects begin on the day babies with cystic fibrosis are born, as they do in piglets with cystic fibrosis. That timing suggests that preventive measures should be initiated immediately. Cystic fibrosis clinics already have substantial momentum toward earlier intervention, and data provide support for that trend.

Second, the loss of CFTR delivers multiple “hits.” This loss does not completely eliminate any single defense; instead, it reduces the effectiveness of at least two defenses — mucociliary transport and antimicrobial activity^{44,52} — and other defenses may also be degraded^{6,10} (Fig. 5). Compromising one host-defense mechanism places a greater burden on other defenses. If those are also impaired, problems may ensue. For example, without robust antimicrobial activity to rapidly kill bacteria, increased numbers of viable organisms might prompt submucosal-gland secretion, leading to impairment of mucociliary transport. Likewise, failure of mucus detachment might allow bacteria to grow under conditions that promote resistance to antibacterial defenses that are already diminished by cystic fibrosis.^{44,73} Thus, partially disrupting two or more defenses may elicit a vicious cycle of disease.

Third, cystic fibrosis initially causes an “equal opportunity” host-defense defect that may serve as a gateway for infection with typical cystic fibrosis-associated bacteria. The mix of many different bacterial species in the airways so early in the disease could elicit inflammatory, remodeling, and structural changes that become irreversible and that confer a predisposition to more intractable infections with typical cystic fibrosis pathogens. We speculate that preventive interventions and antibacterial treatments should not wait for the appearance of *P. aeruginosa* or “typical” pathogens that are associated with cystic fibrosis.

Fourth, correcting even one host-defense defect might be beneficial. For example, treating cystic fibrosis with antibiotics may improve a person’s clinical status, even though it does not address mucus abnormalities. Another example is primary ciliary dyskinesia, which completely obliterates one defense — mucociliary transport — yet causes less severe lung disease than cystic fibrosis.⁷⁴ Lung disease might be less severe in primary ciliary dyskinesia because other defenses (e.g., antimicrobial activity) are intact, although differences in the way these diseases impair mucociliary transport might also explain the differing severity.

Fifth, environmental insults may trigger airway disease in the lungs of people with cystic fibrosis. Another “hit” to airways in persons with this disease might come from infections, environmental injuries, or both. Such insults trigger protective responses, including mucus secretion from the

submucosal glands. But in cystic fibrosis, what would normally be a protective reflex might further cripple mucociliary transport.

Sixth, cystic fibrosis lung disease may begin in large and small airways. On the basis of histopathological findings in infants who die within weeks to months after birth, it is often thought that this disease begins in small airways. However, rapidly advancing inflammation and remodeling confound interpretation about the initiating location. Histopathological studies of older pigs with cystic fibrosis have detected disease in both large and small airways.^{26,27,29} Large airways have antibacterial and mucociliary transport defects at birth, which suggests that they are a susceptible site for the onset of disease. However, small airways also express CFTR,⁷⁵ they probably have defective antibacterial activity, and mucociliary transport in these airways might be impaired by goblet cell-derived mucus. Thus, small airways may also be an initial site of clinical abnormalities. Another consideration is that the total area of small airways is much greater than that of large airways, and thus if physiological defects in both airways were equal on a per-square-meter basis, small airways would be overrepresented.

Seventh, infants with cystic fibrosis may have congenital airway defects. The airway and nasal sinus defects might affect disease progression and complicate assessments. For example, if air trapping is due in part to a congenital defect, rather than to inflammation and abnormal mucus alone, attempting to “treat” on the basis of the appearance of air trapping might not be entirely appropriate.

Eighth, we need better assays of early cystic fibrosis airway disease in humans. Sensitive assays could potentially identify and quantify early host-defense defects and track disease progression and therapeutic interventions. Studies in animal models suggest that assays of the pH of airway-surface liquid, antimicrobial activity, or mucociliary transport could be informative, especially if they are sensitive. For example, the development of methods that assay mucociliary transport in humans with the data granularity achieved in pigs could transform pulmonary imaging of mucociliary transport in cystic fibrosis and possibly other airway diseases.

Finally, these discoveries in cystic fibrosis may also have implications for other diseases. First, they emphasize the value of an animal model

that replicates human disease. Second, they highlight the importance of investigating disease at its genesis and before the onset of secondary manifestations. Manifestations of advanced disease may not reflect the initiating events, and without such knowledge, treatments and preventions may not be as effective as they could be. Pulmonary fibrosis is perhaps another respiratory disease in which investigation before clinical manifestations could be revealing. Third, multiple, partial, perhaps even subtle impairments, or “hits,” can have a profound effect. That concept may be relevant to more common pulmonary diseases

such as asthma and chronic obstructive pulmonary disease, as well as to nonrespiratory diseases.

The origins and initiating factors in cystic fibrosis lung disease probably determine the progression, severity, and disease burden later in life. Understanding the origins, quantifying the initial defects, and intervening early could make a big difference for people with this disease.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Drs. Marcus Nashelsky and Morris Dailey of the University of Iowa, Department of Pathology, for assistance with archival autopsy data and Dr. Mahmoud Abou Alaiwa and Mr. Shawn Roach for assistance with earlier versions of the figures.

REFERENCES

- Rjordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989;245:1066-73. [Erratum, *Science* 1989;245:1437.]
- Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. *The metabolic and molecular basis of inherited disease*. 8th ed. New York: McGraw-Hill, 2001:5121-89.
- Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. *J Pediatr* 2009; 155(5):623.e1-8.e1.
- Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. *Physiol Rev* 1999;79:Suppl:S3-S22.
- Wine JJ, Joo NS. Submucosal glands and airway defense. *Proc Am Thorac Soc* 2004;1:47-53.
- Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? *Respir Res* 2003; 4:8.
- Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. *Am J Physiol Cell Physiol* 2003;284: C2-C15.
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. *N Engl J Med* 2005;352:1992-2001.
- Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. *Annu Rev Med* 2007;58:157-70.
- Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. *Nat Med* 2012;18:509-19.
- Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. *Am J Respir Crit Care Med* 1995;151:1075-82.
- Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. *Am J Respir Crit Care Med* 1997; 156:1197-204.
- Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. *Am J Respir Crit Care Med* 2009;180:146-52.
- Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry annual data report 2012 (<http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf>).
- Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. *N Engl J Med* 2010;363:1991-2003.
- Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011;365:1663-72.
- Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. *Am J Respir Crit Care Med* 2012;186: 593-7.
- Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. *Physiol Rev* 1999;79:Suppl: S193-S214.
- Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. *Science* 2008;321:1837-41.
- Sun X, Sui H, Fisher JT, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. *J Clin Invest* 2010;120:3149-60.
- Tuggle KL, Birket SE, Cui X, et al. Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats. *PLoS One* 2014;9(3):e91253.
- Rogers CS, Abraham WM, Brogden KA, et al. The porcine lung as a potential model for cystic fibrosis. *Am J Physiol Lung Cell Mol Physiol* 2008;295:L240-L263.
- Meyerholz DK, Stoltz DA, Pezzulo AA, Welsh MJ. Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. *Am J Pathol* 2010;176:1377-89.
- Pierucci-Alves F, Akoyev V, Stewart JC III, Wang LH, Janardhan KS, Schultz BD. Swine models of cystic fibrosis reveal male reproductive tract phenotype at birth. *Biol Reprod* 2011;85:442-51.
- Uc A, Olivier AK, Griffin MA, et al. Glycemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass. *Clin Sci (Lond)* 2015;128:131-42.
- Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. *Sci Transl Med* 2010;2:29ra31.
- Ostedgaard LS, Meyerholz DK, Chen J-H, et al. The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. *Sci Transl Med* 2011; 3:74ra24.
- Chang EH, Pezzulo AA, Meyerholz DK, et al. Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. *Laryngoscope* 2012;122:1898-905.
- Stoltz DA, Rokhlina T, Ernst SE, et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. *J Clin Invest* 2013;123:2685-93.
- Olivier AK, Yi Y, Sun X, et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. *J Clin Invest* 2012;122:3755-68.
- Fisher JT, Tyler SR, Zhang Y, et al. Bioelectric characterization of epithelia from neonatal CFTR knockout ferrets. *Am J Respir Cell Mol Biol* 2013;49:837-44.
- Sun X, Olivier AK, Liang B, et al. Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets. *Am J Respir Cell Mol Biol* 2014;50:502-12.
- Sun X, Olivier AK, Yi Y, et al. Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets. *Am J Pathol* 2014; 184:1309-22.

34. Hall GL, Logie KM, Parsons F, et al. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. *PLoS One* 2011;6(8):e23932.
35. Hoo AF, Thia LP, Nguyen TT, et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. *Thorax* 2012;67:874-81.
36. Woodworth BA, Ahn C, Flume PA, Schlosser RJ. The delta F508 mutation in cystic fibrosis and impact on sinus development. *Am J Rhinol* 2007;21:122-7.
37. Trezise AE, Chambers JA, Wardle CJ, Gould S, Harris A. Expression of the cystic fibrosis gene in human foetal tissues. *Hum Mol Genet* 1993;2:213-8.
38. Meyerholz DK, Stoltz DA, Namati E, et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. *Am J Respir Crit Care Med* 2010;182:1251-61.
39. Bonvin E, Le Rouzic P, Bernaudin JF, et al. Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice. *J Physiol* 2008;586:3231-43.
40. Adam RJ, Michalski AS, Bauer C, et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. *Am J Respir Crit Care Med* 2013;188:1434-41.
41. Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. *Am J Pathol* 1982;106:303-11.
42. Fischer AJ, Singh SB, Adam RJ, et al. Tracheomalacia is associated with lower FEV1 and *Pseudomonas* acquisition in children with CF. *Pediatr Pulmonol* 2014;49:960-70.
43. Chen J-H, Stoltz DA, Karp PH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. *Cell* 2010;143:911-23.
44. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. *Nature* 2012;487:109-13.
45. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. *J Intern Med* 2007;261:5-16.
46. Hobbs CA, Da Tan C, Tarran R. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease? *J Physiol* 2013;591:4377-87.
47. Stutts MJ, Canessa CM, Olsen JC. CFTR as a cAMP-dependent regulator of sodium channels. *Science* 1995;269:847-50.
48. Itani OA, Chen JH, Karp PH, et al. Human cystic fibrosis airway epithelia have reduced Cl⁻ conductance but not increased Na⁺ conductance. *Proc Natl Acad Sci U S A* 2011;108:10260-5.
49. Quinton PM. Cystic fibrosis: lessons from the sweat gland. *Physiology (Bethesda)* 2007;22:212-25.
50. Joo NS, Irokawa T, Robbins RC, Wine JJ. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. *J Biol Chem* 2006;281:7392-8.
51. Poulsen JH, Fischer H, Illek B, Machen TE. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. *Proc Natl Acad Sci U S A* 1994;91:5340-4.
52. Hoegger MJ, Fischer AJ, McMenimen JD, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. *Science* 2014;345:818-22.
53. Smith JJ, Welsh MJ. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. *J Clin Invest* 1992;89:1148-53.
54. Coakley RD, Grubb BR, Paradiso AM, et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. *Proc Natl Acad Sci U S A* 2003;100:16083-8.
55. Song Y, Salinas D, Nielson DW, Verkman AS. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. *Am J Physiol Cell Physiol* 2006;290:C741-C749.
56. Abou Alaiwa MH, Beer AM, Pezzulo AA, et al. Neonates with cystic fibrosis have a reduced nasal liquid pH: a small pilot study. *J Cyst Fibros* 2014;13:373-7.
57. McShane D, Davies JC, Davies MG, Bush A, Geddes DM, Alton EW. Airway surface pH in subjects with cystic fibrosis. *Eur Respir J* 2003;21:37-42.
58. Garland AL, Walton WG, Coakley RD, et al. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. *Proc Natl Acad Sci U S A* 2013;110:15973-8.
59. Tirouvanziam R, de Bentzmann S, Hubeau C, et al. Inflammation and infection in naive human cystic fibrosis airway grafts. *Am J Respir Cell Mol Biol* 2000;23:121-7.
60. Gangell C, Gard S, Douglas T, et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. *Clin Infect Dis* 2011;53:425-32.
61. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. *Proc R Soc Lond Biol* 1922;93:306-17.
62. Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. *Curr Opin Immunol* 2001;13:89-95.
63. Singh PK, Tack BF, McCray PB Jr, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. *Am J Physiol Lung Cell Mol Physiol* 2000;279:L799-L805.
64. Fahy JV, Dickey BF. Airway mucus function and dysfunction. *N Engl J Med* 2010;363:2233-47.
65. Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. *Pediatr Pulmonol* 2002;33:293-306.
66. McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, Alton EW. Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. *Eur Respir J* 2004;24:95-100.
67. Hoegger MJ, Awadalla M, Namati E, et al. Assessing mucociliary transport of single particles in vivo shows variable speed and preference for the ventral trachea in newborn pigs. *Proc Natl Acad Sci U S A* 2014;111:2355-60.
68. Trout L, Gatzky JT, Ballard ST. Acetylcholine-induced liquid secretion by bronchial epithelium: role of Cl⁻ and HCO₃⁻ transport. *Am J Physiol* 1998;275:L1095-9.
69. Birket SE, Chu KK, Liu L, et al. A functional anatomic defect of the cystic fibrosis airway. *Am J Respir Crit Care Med* 2014;190:421-32.
70. Joo NS, Cho HJ, Khansaheb M, Wine JJ. Hyposecretion of fluid from tracheal submucosal glands of CFTR-deficient pigs. *J Clin Invest* 2010;120:3161-6.
71. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. *Lancet* 2008;372:415-7.
72. Gustafsson JK, Ermund A, Ambort D, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. *J Exp Med* 2012;209:1263-72.
73. Staudinger BJ, Muller JF, Halldórsson S, et al. Conditions associated with the cystic fibrosis defect promote chronic *Pseudomonas aeruginosa* infection. *Am J Respir Crit Care Med* 2014;189:812-24.
74. Cohen-Cymbberknoh M, Shimonovsky N, Hiller N, Gileles Hillel A, Shoseyov D, Kerem E. Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. *Chest* 2014;145:738-44.
75. Shamsuddin AK, Quinton PM. Surface fluid absorption and secretion in small airways. *J Physiol* 2012;590:3561-74.

Copyright © 2015 Massachusetts Medical Society.